[go: up one dir, main page]

ES2189002T3 - Procedimiento in vitro y utilizacion de composiciones farmaceuticas para el tratamiento de celulas ciliares del oido interno. - Google Patents

Procedimiento in vitro y utilizacion de composiciones farmaceuticas para el tratamiento de celulas ciliares del oido interno.

Info

Publication number
ES2189002T3
ES2189002T3 ES97949346T ES97949346T ES2189002T3 ES 2189002 T3 ES2189002 T3 ES 2189002T3 ES 97949346 T ES97949346 T ES 97949346T ES 97949346 T ES97949346 T ES 97949346T ES 2189002 T3 ES2189002 T3 ES 2189002T3
Authority
ES
Spain
Prior art keywords
internal ear
treatment
pharmaceutical compositions
vitro procedure
ciliary cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97949346T
Other languages
English (en)
Inventor
Wei-Qiang Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2189002T3 publication Critical patent/ES2189002T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNAS COMPOSICIONES, UNOS PROCEDIMIENTOS Y UNOS DISPOSITIVOS QUE FAVORECEN O REFUERZAN EL CRECIMIENTO, LA PROLIFERACION O LA REGENERACION DE LOS TEJIDOS DEL OIDO INTERNO Y EN PARTICULAR DE LOS PELOS AUDITIVOS DEL OIDO INTERNO. ESTA INVENCION SE REFIERE TAMBIEN A UNAS COMPOSICIONES Y UNOS PROCEDIMIENTOS DE PROFILAXIS Y DE TRATAMIENTO DE LOS MAMIFEROS AFECTADOS POR TRASTORNOS DEL OIDO INTERNO O DE ESTADOS VINCULADOS EN PARTICULAR A UNOS DEFECTOS DE AUDICION DEBIDOS A LESIONES DE DICHOS PELOS O A SU PERDIDA O SU DEGENERACION, MEDIANTE ADMINISTRACION DE UNA DOSIS CON EFECTO TERAPEUTICO DE IGF - 1, O DE FGF - 2, O DE SUS AGONISTAS, SOLOS O COMBINADOS.
ES97949346T 1996-11-01 1997-10-28 Procedimiento in vitro y utilizacion de composiciones farmaceuticas para el tratamiento de celulas ciliares del oido interno. Expired - Lifetime ES2189002T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2953696P 1996-11-01 1996-11-01
US08/743,267 US6593290B1 (en) 1996-11-01 1996-11-04 Treatment of inner ear hair cells

Publications (1)

Publication Number Publication Date
ES2189002T3 true ES2189002T3 (es) 2003-07-01

Family

ID=26705049

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97949346T Expired - Lifetime ES2189002T3 (es) 1996-11-01 1997-10-28 Procedimiento in vitro y utilizacion de composiciones farmaceuticas para el tratamiento de celulas ciliares del oido interno.

Country Status (15)

Country Link
US (1) US6593290B1 (es)
EP (1) EP0948349B1 (es)
JP (1) JP4191252B2 (es)
CN (1) CN1313147C (es)
AR (1) AR009603A1 (es)
AT (1) ATE229815T1 (es)
AU (1) AU724988B2 (es)
BR (1) BR9712468A (es)
CA (1) CA2268331C (es)
DE (1) DE69718053T2 (es)
DK (1) DK0948349T3 (es)
ES (1) ES2189002T3 (es)
IL (2) IL129381A0 (es)
WO (1) WO1998019700A1 (es)
ZA (1) ZA979814B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US7053200B1 (en) 1999-06-01 2006-05-30 Baylor College Of Medicine Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
US6838444B1 (en) 1999-06-01 2005-01-04 Baylor College Of Medicine Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
AU4885500A (en) * 1999-07-27 2001-02-01 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
AU2001288219C1 (en) * 2000-07-11 2009-12-03 Sound Pharmaceuticals Incorporated Stimulation of cellular regeneration and differentiation in the inner ear
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
CA2500278A1 (en) * 2002-10-02 2004-04-15 Anges Mg, Inc. Pharmaceutical preparation for hearing impairment
PL2248899T3 (pl) 2003-03-19 2015-10-30 Biogen Ma Inc Białko wiążące receptor nogo
ES2395094T3 (es) 2004-06-24 2013-02-08 Biogen Idec Ma Inc. Tratamiento de afecciones que implican la desmielinización
US20070082858A1 (en) * 2004-12-21 2007-04-12 Oregon Health & Science University Methods and compositions for the prevention of toxic side effects of aminoglycoside medications
CN101495509B (zh) 2005-07-08 2015-04-22 比奥根艾迪克Ma公司 Sp35抗体及其用途
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
US20070190127A1 (en) 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
AU2008325107B2 (en) * 2007-11-08 2015-04-23 Biogen Ma Inc. Use of LINGO-4 antagonists in the treatment of conditions involving demyelination
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8447409B2 (en) * 2008-10-15 2013-05-21 Cochlear Limited Electroneural interface for a medical implant
US7934558B2 (en) 2009-03-13 2011-05-03 Halliburton Energy Services, Inc. System and method for dynamically adjusting the center of gravity of a perforating apparatus
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
AU2013262934B2 (en) 2012-05-14 2018-02-01 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
PL3702443T3 (pl) 2013-03-14 2022-05-16 The Brigham And Women's Hospital, Inc. Kompozycje i sposoby ekspansji i hodowli nabłonkowych komórek macierzystych
IL299964A (en) * 2014-09-03 2023-03-01 Massachusetts Inst Technology Preparations, systems and methods for producing hair cells in the inner ear to treat hearing loss
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
EP3400286A1 (en) 2016-01-08 2018-11-14 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
WO2017210553A1 (en) * 2016-06-03 2017-12-07 Hough Ear Institute Combination therapies for inner ear sensory hair cell regeneration/replacement
CN106075392B (zh) * 2016-07-18 2020-07-07 滨州医学院 促红细胞生成素衍生物在听力保护上的应用
CN110392686A (zh) 2016-12-30 2019-10-29 频率治疗公司 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
CA3109647A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
CN109182250A (zh) * 2018-09-30 2019-01-11 山东省立医院 一种小鼠耳蜗毛细胞培养方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4637402A (en) 1980-04-28 1987-01-20 Adelman Roger A Method for quantitatively measuring a hearing defect
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS607934A (ja) 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソ−ムの製造方法
EP0350973B1 (de) 1983-09-26 1997-11-05 Udo Dr. Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
AU598205B2 (en) 1985-08-22 1990-06-21 Gropep Pty Ltd Peptide analogues of mammalian insulin-like growth factor-1
US5439818A (en) 1985-09-12 1995-08-08 Scios Nova Inc. DNA encoding human recombinant basic fibroblast growth factor
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
ES2007309T3 (es) 1987-04-23 1994-11-01 Monsanto Co Secrecion del factor de crecimiento insulinoide 1 en e.coli.
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5352589A (en) 1988-09-16 1994-10-04 Farmitalia Carlo Erba S.R.L. Deletion mutant of basic fibroblast growth factor and production thereof
US5464943A (en) 1989-04-26 1995-11-07 Takeda Chemical Industries, Ltd. DNA encoding glycosylated FGF and production thereof
US5364839A (en) * 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
US5187151A (en) 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
DK0585368T3 (da) 1991-04-25 1998-03-16 Univ Brown Res Found Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter
AU654574B2 (en) * 1991-06-14 1994-11-10 Amgen, Inc. Collagen film drug delivery for proteins
WO1993010810A1 (en) * 1991-11-27 1993-06-10 Institute Of Molecular Biology, Inc. Bone regeneration
US5482929A (en) 1991-12-26 1996-01-09 Kaken Pharmaceutical Co., Ltd. Composition of stabilized fibroblast growth factor
DE69309920T2 (de) 1992-04-04 1997-11-20 Medical Research Council, London Prüfung des gehörs
DE69331802T2 (de) * 1992-08-26 2002-11-07 Celtrix Pharmaceuticals, Inc. Verfahren zur systemischen behandlung katabolischer zustände und systemischer gewebeschädigung
US5407913A (en) 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
EP0802800B1 (en) 1993-08-12 2002-06-12 Neurotech S.A. Biocompatible immunoisolatory capsules containing genetically altered cells for the delivery of biologically active molecules
US6136785A (en) * 1995-08-08 2000-10-24 University Of Virginia Patent Foundation Protection from loss of sensory hair cells in the inner ear by administration of insulin-like growth factor and platelet derived growth factor

Also Published As

Publication number Publication date
AU724988B2 (en) 2000-10-05
IL129381A0 (en) 2000-02-17
CA2268331C (en) 2011-07-26
DE69718053T2 (de) 2003-09-11
JP4191252B2 (ja) 2008-12-03
WO1998019700A1 (en) 1998-05-14
AU7000698A (en) 1998-05-29
US6593290B1 (en) 2003-07-15
CN1313147C (zh) 2007-05-02
ATE229815T1 (de) 2003-01-15
JP2002514191A (ja) 2002-05-14
ZA979814B (en) 1999-04-30
DE69718053D1 (de) 2003-01-30
EP0948349B1 (en) 2002-12-18
IL129381A (en) 2006-07-05
EP0948349A1 (en) 1999-10-13
AR009603A1 (es) 2000-04-26
BR9712468A (pt) 1999-10-26
CA2268331A1 (en) 1998-05-14
CN1251531A (zh) 2000-04-26
DK0948349T3 (da) 2003-04-07

Similar Documents

Publication Publication Date Title
ES2189002T3 (es) Procedimiento in vitro y utilizacion de composiciones farmaceuticas para el tratamiento de celulas ciliares del oido interno.
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
ES2176343T3 (es) Composiciones sanadoras de tratamiento de heridas causadas por el acne que contienen un piruvano, un antioxidante y una mezcla de acidos grasos.
ES2147294T3 (es) Compuestos terapeuticos.
ES2144980T1 (es) Metodos y composiciones para tratar la rinitis alergica y otros trastornos, empleando descarboetoxiloratadina.
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
DE60041010D1 (de) Therapeutische Vorrichtung
BR9707325A (pt) Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma
ES2060775T3 (es) Egf para la prevencion de daños en tejidos despues de un episodio isquemico.
ES2170938T3 (es) Utilizacion del factor neurotrofico derivado de celulas gliales (gdnf) para el tratamiento de las deficiencias auditivas.
CU23226B7 (es) COMPOSICIONES ANALGéSICAS QUE COMPRENDEN COMPUESTOS ANTI-EPILéPTICOS Y ANTINFLAMATORIOS NO ESTEROIDEOS
PT1086702E (pt) Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca
PT1173197E (pt) Intervencao metabolica com glp-1, para melhorar a funcao do tecido isquemico e reperfundido
PA8487601A1 (es) Derivados biciclicos sustituidos utiles como agentes contra el cancer
NO20026171D0 (no) Topiske farmasöytiske formuleringer og fremgangsmåter for behandling
ES2115727T3 (es) Esponja para la cornea.
AR015360A1 (es) Proceso para la manufactura de una composicion farmaceutica para reducir o prevenir los efectos de la inflamacion; dicha composicion farmaceutica y unelemento para aplicar la composicion farmaceutica en dicho proceso
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
PT1239849E (pt) Formulacoes farmaceuticas que compreendem resveratrol e a sua utilizacao
ES2149971T3 (es) Derivados 5-sustituidos del acido micofenolico.
ES2168359T3 (es) Acido micofenolico 6-sustituido y derivados con actividad inmunosupresora.
ES2063033T3 (es) Empleo de igf-ii en el tratamiento de la enfermedades de los huesos.
ES2227684T3 (es) Albumina como ingrediente activo para el tratamiento de lesiones conjuntivas y de la cornea y del ojo seco.
ES2194918T3 (es) Compuestos de tiazol y tiadiazol como ligando receptor de dopamina d3.
AR020660A1 (es) Composiciones antibioticas para el tratamiento de ojos, oidos y nariz